metformin has been researched along with Malignant Mesothelioma in 4 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Metformin suppressed cell growth of 9 kinds of mesothelioma including immortalized cells of mesothelium origin irrespective of the p53 functional status, whereas susceptibility to nutlin-3a was partly dependent on the p53 genotype." | 7.85 | Metformin produces growth inhibitory effects in combination with nutlin-3a on malignant mesothelioma through a cross-talk between mTOR and p53 pathways. ( Hiroshima, K; Morinaga, T; Namiki, T; Sekine, I; Shimada, H; Shimazu, K; Shingyoji, M; Tada, Y; Tagawa, M; Tatsumi, K, 2017) |
| "This study aimed to investigate the effect of metformin on survival of people with type 2 diabetes and pleural mesothelioma." | 7.83 | Metformin and survival of people with type 2 diabetes and pleural mesothelioma: A population-based retrospective cohort study. ( Brewster, DH; Damhuis, RA; Walker, J; Wild, SH; Wu, H, 2016) |
| "Metformin suppressed cell growth of 9 kinds of mesothelioma including immortalized cells of mesothelium origin irrespective of the p53 functional status, whereas susceptibility to nutlin-3a was partly dependent on the p53 genotype." | 3.85 | Metformin produces growth inhibitory effects in combination with nutlin-3a on malignant mesothelioma through a cross-talk between mTOR and p53 pathways. ( Hiroshima, K; Morinaga, T; Namiki, T; Sekine, I; Shimada, H; Shimazu, K; Shingyoji, M; Tada, Y; Tagawa, M; Tatsumi, K, 2017) |
| "This study aimed to investigate the effect of metformin on survival of people with type 2 diabetes and pleural mesothelioma." | 3.83 | Metformin and survival of people with type 2 diabetes and pleural mesothelioma: A population-based retrospective cohort study. ( Brewster, DH; Damhuis, RA; Walker, J; Wild, SH; Wu, H, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Shukla, SK | 1 |
| Chan, A | 1 |
| Parvathaneni, V | 1 |
| Gupta, V | 1 |
| Shimazu, K | 1 |
| Tada, Y | 1 |
| Morinaga, T | 1 |
| Shingyoji, M | 1 |
| Sekine, I | 1 |
| Shimada, H | 1 |
| Hiroshima, K | 1 |
| Namiki, T | 1 |
| Tatsumi, K | 1 |
| Tagawa, M | 1 |
| Lennon, FE | 1 |
| Cianci, GC | 1 |
| Kanteti, R | 1 |
| Riehm, JJ | 1 |
| Arif, Q | 1 |
| Poroyko, VA | 1 |
| Lupovitch, E | 1 |
| Vigneswaran, W | 1 |
| Husain, A | 1 |
| Chen, P | 1 |
| Liao, JK | 1 |
| Sattler, M | 1 |
| Kindler, HL | 1 |
| Salgia, R | 1 |
| Wu, H | 1 |
| Walker, J | 1 |
| Damhuis, RA | 1 |
| Brewster, DH | 1 |
| Wild, SH | 1 |
4 other studies available for metformin and Malignant Mesothelioma
| Article | Year |
|---|---|
Metformin-loaded chitosomes for treatment of malignant pleural mesothelioma - A rare thoracic cancer.
Topics: Antineoplastic Agents; Cell Line, Tumor; Chitosan; Delayed-Action Preparations; Drug Liberation; Hum | 2020 |
Metformin produces growth inhibitory effects in combination with nutlin-3a on malignant mesothelioma through a cross-talk between mTOR and p53 pathways.
Topics: Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Humans; Imidazoles; Lung Ne | 2017 |
Unique fractal evaluation and therapeutic implications of mitochondrial morphology in malignant mesothelioma.
Topics: Cell Line, Tumor; Cisplatin; Fractals; Glycolysis; Humans; Lung Neoplasms; Mesothelioma; Mesotheliom | 2016 |
Metformin and survival of people with type 2 diabetes and pleural mesothelioma: A population-based retrospective cohort study.
Topics: Aged; Aged, 80 and over; Cause of Death; Cohort Studies; Diabetes Mellitus, Type 2; Female; Humans; | 2016 |